Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06526819
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-24
Brief Title:
A Phase 12 Study of SMP-3124LP in Adults with Advanced Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-label Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An Open-label Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety Tolerability Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Detailed Description:
Phase 12 global multicenter open-label first-in-human clinical study to evaluate the safety tolerability pharmacokinetics and preliminary antitumor activity of SMP-3124
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None